KALA BIO INC KALA
COM · Common Stock · CUSIP 483119301
Company in Waltham, United States
- SectorHealth care
- IndustryPharmaceutical Preparations
- HeadquartersArlington, MA
- Founded2009
- Websitekalarx.com
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Shares outstanding: 19.3m as of 2026-08-14, from the company's own SEC filing; the percentage can still exceed 100%: lent-out shares are counted by the lender and the buyer, and some reports overlap without saying so. Implied quarter-end price ≈ $1.73.
Biggest buyers
| VANGUARD CAPITAL MANAGEMENT LLC | New | +220.6k |
| GEODE CAPITAL MANAGEMENT, LLC | New | +145.2k |
| VANGUARD FIDUCIARY TRUST CO | New | +101.4k |
| BlackRock, Inc. | New | +71.5k |
| NORTHERN TRUST CORP | New | +41.6k |
| Qube Research & Technologies Ltd | New | +11.1k |
| GOLDMAN SACHS GROUP INC | New | +10.9k |
| UBS Group AG | New | +9.1k |
| Tower Research Capital LLC (TRC) | New | +616 |
| BARCLAYS PLC | New | +608 |
Biggest sellers
| None |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
| Labkowski Nachum 13G · passive investor new · filed 2026-10-19 | 5.0% |
Fell to 5% or below in the last year: Lazar David E. (3.9%, 2026-07-02), BAKER BROS. ADVISORS LP (0.0%, 2026-05-15)
Insider purchases and sales since 1 Apr 2026
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
Officers and directors buying vs selling
Number of people, by quarter (10% owners not included)
Numbers
| Quarter | Buying | Bought | Selling | Sold | Sold under a plan |
|---|---|---|---|---|---|
| Q4 2024 | 0 | — | 0 | — | — |
| Q1 2025 | 0 | — | 5 | $106.4k | — |
| Q2 2025 | 0 | — | 5 | $203.5k | — |
| Q3 2025 | 0 | — | 0 | — | — |
| Q4 2025 | 0 | — | 5 | $248.7k | — |
| Q1 2026 | 0 | — | 0 | — | — |
| Q2 2026 | 0 | — | 0 | — | — |
| Q3 2026 | 0 | — | 0 | — | — |
None reported since 1 Apr 2026.
Holders, Q2 2026
| Manager | Shares | Change |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC 0.00% of their portfolio | 220.6k $381.7k | New |
| GEODE CAPITAL MANAGEMENT, LLC 0.00% of their portfolio | 145.2k $251.1k | New |
| VANGUARD FIDUCIARY TRUST CO 0.00% of their portfolio | 101.4k $175.4k | New |
| BlackRock, Inc. 0.00% of their portfolio | 71.5k $123.8k | New |
| NORTHERN TRUST CORP 0.00% of their portfolio | 41.6k $72.0k | New |
| Qube Research & Technologies Ltd 0.00% of their portfolio | 11.1k $19.2k | New |
| GOLDMAN SACHS GROUP INC 0.00% of their portfolio | 10.9k $18.9k | New |
| UBS Group AG 0.00% of their portfolio | 9.1k $15.7k | New |
| Tower Research Capital LLC (TRC) 0.00% of their portfolio | 616 $1.1k | New |
| BARCLAYS PLC 0.00% of their portfolio | 608 $1.1k | New |
| MORGAN STANLEY 0.00% of their portfolio | 28 $48 | New |
| Caitong International Asset Management Co., Ltd 0.00% of their portfolio | 10 $17 | New |
| INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC 0.00% of their portfolio | 2 $4 | New |